API sourcing controversy intensifies
As we noted on Twitter, a former HIMS pharmacy VP claimed on an expert call that their semaglutide API comes from “the same place Novo uses.”
Meanwhile, on its annual letter to shareholders, Novo says its API sites are exclusively in Denmark and the U.S., not China — directly contradicting former Hims VP’s claim and muddying the narrative further.
$NVO这垃圾北欧药厂就是纯婊立坊，我从国内信源基本可以确定就是用的一家 
把之前倒腾的利润全吃进去了，插眼关注
